[{"id":"29940bae-2e04-4198-8582-ee2667059194","acronym":"","url":"https://clinicaltrials.gov/study/NCT06406465","created_at":"2024-05-11T04:14:20.188Z","updated_at":"2025-02-25T12:30:34.309Z","phase":"Phase 2","brief_title":"A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity","source_id_and_acronym":"NCT06406465","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1 • UGT1A1*28 + UGT1A1*6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 07/30/2027","primary_completion_date":" 07/30/2027","study_txt":" Completion: 07/30/2028","study_completion_date":" 07/30/2028","last_update_posted":"2025-02-24"},{"id":"65d9c2cb-0676-43e5-831c-bcc76a373ee1","acronym":"RESOLVE","url":"https://clinicaltrials.gov/study/NCT05154994","created_at":"2021-12-13T14:12:40.514Z","updated_at":"2025-02-25T12:38:04.917Z","phase":"Phase 1","brief_title":"Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma","source_id_and_acronym":"NCT05154994 - RESOLVE","lead_sponsor":"University of Utah","biomarkers":" ARID1A","pipe":"","alterations":" ","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)"],"overall_status":"Suspended","enrollment":" Enrollment 9","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-24"},{"id":"5c523880-f8a6-448f-8403-e3010aefe575","acronym":"","url":"https://clinicaltrials.gov/study/NCT03772925","created_at":"2021-01-18T18:39:51.839Z","updated_at":"2025-02-25T14:40:05.004Z","phase":"Phase 1","brief_title":"Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT03772925","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • CD4","pipe":" | ","alterations":" TP53 mutation • FLT3 mutation","tags":["BCL2 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pevonedistat (MLN4924) • Beleodaq (belinostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/20/2019","start_date":" 06/20/2019","primary_txt":" Primary completion: 06/16/2025","primary_completion_date":" 06/16/2025","study_txt":" Completion: 06/16/2025","study_completion_date":" 06/16/2025","last_update_posted":"2025-02-14"},{"id":"e0eae0c1-fbd3-4860-8074-47f0db5f46f5","acronym":"CHARGE","url":"https://clinicaltrials.gov/study/NCT04315233","created_at":"2021-01-18T20:54:52.326Z","updated_at":"2025-02-25T15:43:56.139Z","phase":"Phase 1","brief_title":"Ribociclib\u0026Belinostat In Patients w Metastatic Triple Neg Breast Cancer \u0026 Recurrent Ovarian Cancer w Response Prediction By Genomics","source_id_and_acronym":"NCT04315233 - CHARGE","lead_sponsor":"University of Utah","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 05/03/2021","start_date":" 05/03/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-10-30"},{"id":"88d90e77-172d-4510-b158-f4795d53f576","acronym":"CRESCENDO","url":"https://clinicaltrials.gov/study/NCT06072131","created_at":"2023-10-10T15:12:06.102Z","updated_at":"2024-07-02T16:35:00.782Z","phase":"Phase 3","brief_title":"To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL","source_id_and_acronym":"NCT06072131 - CRESCENDO","lead_sponsor":"Acrotech Biopharma Inc.","biomarkers":" ALK • TNFRSF8 • UGT1A1","pipe":" | ","alterations":" TNFRSF8 expression • UGT1A1*1*1","tags":["ALK • TNFRSF8 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 expression • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Beleodaq (belinostat) • Folotyn (pralatrexate)"],"overall_status":"Recruiting","enrollment":" Enrollment 504","initiation":"Initiation: 10/04/2023","start_date":" 10/04/2023","primary_txt":" Primary completion: 07/01/2030","primary_completion_date":" 07/01/2030","study_txt":" Completion: 11/01/2030","study_completion_date":" 11/01/2030","last_update_posted":"2024-05-27"},{"id":"5f6cead8-271a-4f4a-b549-d12536680be3","acronym":"ETCTN","url":"https://clinicaltrials.gov/study/NCT04340843","created_at":"2023-11-13T22:14:48.481Z","updated_at":"2024-07-02T16:35:03.396Z","phase":"Phase 2","brief_title":"Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma","source_id_and_acronym":"NCT04340843 - ETCTN","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":"","alterations":" ","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • Beleodaq (belinostat) • guadecitabine (SGI-110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-16"},{"id":"e4a4b657-550e-4739-b71c-fff75613dfbe","acronym":"ETCTN 10500","url":"https://clinicaltrials.gov/study/NCT05627245","created_at":"2022-11-25T15:58:14.707Z","updated_at":"2024-07-02T16:35:09.644Z","phase":"Phase 1","brief_title":"Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment","source_id_and_acronym":"NCT05627245 - ETCTN 10500","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EZH2","pipe":" | ","alterations":" RAS wild-type • EZH2 mutation • EZH2 wild-type","tags":["EZH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • EZH2 mutation • EZH2 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat) • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-04-15"},{"id":"510fc7b1-5e2b-4ee3-99f2-59c857b1e454","acronym":"","url":"https://clinicaltrials.gov/study/NCT04703920","created_at":"2021-01-19T20:51:08.937Z","updated_at":"2024-07-02T16:35:23.147Z","phase":"Phase 1","brief_title":"Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer","source_id_and_acronym":"NCT04703920","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/04/2021","start_date":" 03/04/2021","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-01-17"},{"id":"adcfb6e9-0452-4b32-ad00-396c0e485aca","acronym":"","url":"https://clinicaltrials.gov/study/NCT02737046","created_at":"2024-01-02T16:17:17.749Z","updated_at":"2024-07-02T16:35:24.777Z","phase":"Phase 2","brief_title":"Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma","source_id_and_acronym":"NCT02737046","lead_sponsor":"University of Miami","biomarkers":" IFNA1","pipe":"","alterations":" ","tags":["IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Beleodaq (belinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/12/2016","start_date":" 12/12/2016","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-01-01"},{"id":"fddf2292-64cd-484d-a9d7-9f0156727a0f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02680795","created_at":"2021-09-14T22:55:07.908Z","updated_at":"2024-07-02T16:36:24.432Z","phase":"Phase 1","brief_title":"Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes","source_id_and_acronym":"NCT02680795","lead_sponsor":"Acrotech Biopharma LLC","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*28 • UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*28 • UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Beleodaq (belinostat)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 04/27/2016","start_date":" 04/27/2016","primary_txt":" Primary completion: 07/21/2020","primary_completion_date":" 07/21/2020","study_txt":" Completion: 07/21/2020","study_completion_date":" 07/21/2020","last_update_posted":"2021-09-14"},{"id":"e7ed921b-0c40-43f6-bd5a-19e029fa28c7","acronym":"BENEFIT","url":"https://clinicaltrials.gov/study/NCT04315155","created_at":"2021-01-18T20:54:51.245Z","updated_at":"2025-02-25T14:29:10.149Z","phase":"Phase 1","brief_title":"Evaluating Safety \u0026 Efficacy Belinostat Combo w Nivo Alone \u0026 w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation","source_id_and_acronym":"NCT04315155 - BENEFIT","lead_sponsor":"University of Utah","biomarkers":" ARID1A","pipe":" | ","alterations":" ARID1A mutation","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Beleodaq (belinostat)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2020-10-28"},{"id":"5e76812d-deb7-4b76-9552-cc9c8c1628b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT00993616","created_at":"2021-01-18T03:52:52.771Z","updated_at":"2024-07-02T16:36:57.793Z","phase":"Phase 2","brief_title":"Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin","source_id_and_acronym":"NCT00993616","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Beleodaq (belinostat)"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 12/01/2009","start_date":" 12/01/2009","primary_txt":" Primary completion: 07/01/2012","primary_completion_date":" 07/01/2012","study_txt":" Completion: 07/29/2012","study_completion_date":" 07/29/2012","last_update_posted":"2019-07-23"},{"id":"23f00988-141d-492a-bf10-8b3f15c78220","acronym":"","url":"https://clinicaltrials.gov/study/NCT01686165","created_at":"2021-01-18T07:18:51.318Z","updated_at":"2024-07-02T16:37:07.396Z","phase":"Phase 2","brief_title":"Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL","source_id_and_acronym":"NCT01686165","lead_sponsor":"University of Arizona","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Zevalin (ibritumomab tiuxetan) • Beleodaq (belinostat)"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 08/31/2012","start_date":" 08/31/2012","primary_txt":" Primary completion: 02/09/2016","primary_completion_date":" 02/09/2016","study_txt":" Completion: 11/09/2017","study_completion_date":" 11/09/2017","last_update_posted":"2018-08-28"}]